ClinicalTrials.gg
Active, not recruitingNCT06635824Updated Nov 3, 2026

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

A Phase 3 interventional study of Acasunlimab and Pembrolizumab in PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC, sponsored by Genmab. Active, not recruiting at 247 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Genmab · Phase 3, Interventional, and Treatment

Updated Nov 3, 202623 sites added23 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
191
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,460 studies in Lung Neoplasms with a site in United States — 422 open to participants now, 643 under way, 52 of them phase 3. Lung Neoplasms · United States.

Enrollment
371st of 1,906
191 · median 48
Started
2024
with 105 others
Phase 3
158 of 2,460
23 open now
Primary completion
2027-07
later than 324 of 637 live
Registered
2,245th of 2,460
by date

Among the 2,460 studies in Lung Neoplasms with a site in United States, this one is the 371st largest by enrollment of the 1,906 interventional ones that give a count, is one of 106 that started in 2024, is one of 158 in phase 3, reaches primary completion later than 324 of the 637 other live ones, and was the 2,245th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

422 of the 2,460 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:

417 more — sign in →

All 422 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,460 studies in Lung Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the locally advanced (unresectable stage IIIB/C) or metastatic setting.

Read the detailed description

The goal of this trial is to determine the efficacy and safety of acasunlimab (an experimental antibody also known as GEN1046 or DuoBody® PDL1x4-1BB) in combination with pembrolizumab (an antibody known as KEYTRUDA®) compared to that of docetaxel (a standard of care chemotherapy). During the trial, the participant's quality of life will also be evaluated using industry-standard scales of measurement. To be eligible, participants must have:

  1. non-small cell lung cancer that are locally advanced, unresectable stage IIIB/C or has metastasized (spread)
  2. tumors that are positive for the PD-L1 protein (a biomarker that may be predictive of response to therapy)
  3. been previously treated with a PD-1/PD-L1-inhibitor and a platinum-containing cancer therapy administered in combination or sequentially (irrespective of the order).

Other eligibility criteria will also apply.

Participants will be assigned to 1 of 2 active therapies, also known as treatment arms, as follows:

  • Acasunlimab (100 milligrams [mg]) and pembrolizumab (400 mg) once every 6 weeks (Q6W), or
  • Docetaxel 75 milligrams per meter squared (mg/m\^2) once every 3 weeks (Q3W).

The estimated trial duration for a participant will vary but may be up to 5 years, consisting of:

  • An optional 3-month pre-screening period
  • A 28-day screening period
  • Up to 2 years of treatment
  • A 90-day safety follow-up period
  • Post-treatment follow-up.
03

Conditions studied

  • PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

Browse trials for

Keywords

  • Lung Cancer
  • Solid Tumors
  • PD-L1
  • 4-1BB
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant has or cytologically confirmed locally advanced (unresectable stage IIIB/C) or NSCLC (stage IV) with known subtype.
  • Participant has progressed radiographically on or after receiving:

    • One (/PD-L1 inhibitor and platinum-based chemotherapy concomitantly) in the locally advanced (unresectable stage IIIB/C) or metastatic disease setting; OR
    • No more than 2 prior lines of therapy (PD-1/PD-L1 inhibitor and platinum-based chemotherapy sequentially, irrespective of the order) in the locally advanced (unresectable stage IIIB/C) or metastatic disease setting.
  • Participant must have positive tumor PD-L1 expression (tumor cells ≥1%) determined prospectively on a tumor sample from the locally advanced (unresectable stage IIIB/C) or metastatic setting at a sponsor-designated central laboratory.
  • Participant has according to v1.1 as assessed by the investigator at baseline.
  • Participant has an (ECOG) performance status 0 or 1 within 7 days of Cycle 1 Day 1.
  • Participant has a of ≥3 months.
  • Participant must have adequate organ and bone marrow function, per laboratory test results within 7 days of trial treatment.

Key Exclusion Criteria:

  • Documentation of known targetable epidermal growth factor receptor (EGFR) sensitizing mutations, anaplastic lymphoma kinase (ALK), RET proto-oncogene (RET), ROS proto-oncogene 1; receptor tyrosine kinase (ROS1) rearrangement, Kirsten rat sarcoma virus (KRAS), B-Raf proto-oncogene (BRAF) mutations, and MET proto-oncogene; receptor tyrosine kinase (MET) exon 14 skipping mutations/MET amplification. NOTE: MET amplification testing is optional based on local availability of the test.

    • Participants with known KRAS/BRAF mutations are eligible for the trial if they do not have access to targeted therapies.
  • Participants with newly identified, untreated or unstable or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis.
  • Prior treatment with docetaxel for NSCLC.
  • Prior treatment with a 4-1BB (CD137) targeted agent, any type of antitumor vaccine, autologous cell immunotherapy, or any unapproved immunotherapy.
  • Treatment with an anticancer agent within 28 days prior to the first dose of trial treatment.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
191 participants (actual)

Study arms

  • Experimental
    Arm A

    Acasunlimab, 100 mg and pembrolizumab, 400 mg will be administered via intravenous (IV) infusion, once every 6 weeks (Q6W) (Cycle length=42 days).

    Drug: Acasunlimab · Drug: Pembrolizumab

  • Active comparator
    Arm B

    Docetaxel, 75 mg/m\^2 will be administered via IV infusion, once every 3 weeks (Q3W) (Cycle length=21 days).

    Drug: Docetaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from date of randomization to date of death due to any cause.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from the date of randomization to the date of the first documented progression or death due to any cause, whichever occurs first based on response evaluation criteria in solid tumors (RECIST) version 1.1 as assessed by the investigator.

    Time frame: Up to approximately 5 years

  2. Confirmed Overall Response Rate (ORR)

    Confirmed ORR is defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on RECIST v1.1 as assessed by the investigator.

    Time frame: Up to approximately 5 years

  3. Duration of Response (DOR)

    DOR is defined as the time from the onset date of response to the date of the first documented progression or death due to any cause based on RECIST v1.1 as assessed by the investigator.

    Time frame: Up to approximately 5 years

  4. Number of Participants With Adverse Events (AEs)

    Time frame: From first dose until the end of the study (approximately 5 years)

  5. Time to Treatment Discontinuation Due to AE

    Time frame: From first dose until the end of the study (approximately 5 years)

  6. Plasma Concentration of Acasunlimab

    Time frame: Predose and postdose at multiple timepoints in Cycles 1-4 (Cycle length=42 days)

  7. Number of Participants With Anti-drug Antibodies (ADAs) to Acasunlimab

    Serum samples will be analyzed using validated, specific, and sensitive immunoassay method. Samples will be screened for ADAs binding to acasunlimab and the titer of confirmed positive/negative samples will be reported.

    Time frame: Predose and postdose at multiple timepoints in Cycles 1-4 (Cycle length=42 days)

  8. Change From Baseline in Functional Assessment of Cancer Therapy Item GP5 (FACIT-GP5; Version 4) Score

    Participant's global assessment of treatment tolerability will be assessed by FACIT-GP5. FACIT-GP5 asks participants to rate their agreement with the following statement, "I am bothered by side effects of treatment" in the past 7 days. Responses will be captured on a 5-point Likert scale ranging from 0 to 4 indicating 0 as not at all to 4 as very much bothered by side effects.

    Time frame: Baseline up to approximately 2 years

  9. Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    The PRO-CTCAE allows participants to report on the frequency, severity, and interference of patient-reported symptoms. For each AE, there are between one and three items to assess the frequency, severity, and/or interference with activities related to that AE. All PRO-CTCAE responses will be scored from 0 to 4 for frequency indicating (0= never to 4= almost constantly), severity (0= none to 4= very severe) and interference with usual or daily activities (0= not at all to 4= very much).

    Time frame: Up to approximately 2 years

07

Study locations

247 sites

Showing the first 100 of 247 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2027, 32 months after the start.

Of 62 industry-sponsored phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's planned 32 months is below that.

Counting every sponsor, half of 128 studies reached it within 44 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 10, 2024
StartActual
Nov 25, 2024
Primary completionEst.
Jul 30, 2027
CompletionEst.
Sep 30, 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
23 sites added, 23 sites removed
Show 23 added (9 Spain, 4 Germany, 4 Italy, 2 France, 2 Ireland, 2 Puerto Rico)
  • Hopital Saint Joseph - Paris · Paris, France
  • Institut Gustave Roussy · Villejuif, France
  • Evangelische Lungenklinik Berlin · Berlin, Germany
  • Vivantes Klinikum im Friedrichshain · Berlin, Germany
  • Vivantes Klinikum Neukoelln · Berlin, Germany
  • Vivantes Klinikum Spandau · Berlin, Germany
  • Beaumont Hospital · Dublin, Ireland
  • St James's Hospital · Dublin, Ireland
  • Istituto Nazionale per la Ricerca sul Cancro di Genova · Genova, Italy
  • Ospedale Santa Maria delle Croci · Ravenna, Italy
  • Regina Elena National Cancer Institute · Roma, Italy
  • CRC - Centro Ricerche Cliniche di Verona S.r.l. · Verona, Italy
  • Pan American Oncology Trials, LLC · San Juan, Puerto Rico
  • Auxilio Mutuo Cancer Center · San Juan, Puerto Rico
  • Hospital General Universitario Dr. Balmis · Alicante, Spain
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • ICO Girona · Girona, Spain
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitario Virgen de la Victoria · Málaga, Spain
  • Hospital Universitario Virgen del Rocio · Seville, Spain
  • Hospital Universitario Virgen Macarena · Seville, Spain
  • Hospital Universitari i Politecnic La Fe · Valencia, Spain
Show 23 removed
  • Institut Gustave Roussy · Villejuif, France
  • Hopital Saint Joseph - Paris · Paris, France
  • Evangelische Lungenklinik Berlin · Berlin, Germany
  • Vivantes Klinikum im Friedrichshain · Berlin, Germany
  • Vivantes Klinikum Neukoelln · Berlin, Germany
  • Vivantes Klinikum Spandau · Berlin, Germany
  • Beaumont Hospital · Dublin, Ireland
  • St James's Hospital · Dublin, Ireland
  • Istituto Nazionale per la Ricerca sul Cancro di Genova · Genova, Italy
  • Ospedale Santa Maria delle Croci · Ravenna, Italy
  • Regina Elena National Cancer Institute · Roma, Italy
  • CRC - Centro Ricerche Cliniche di Verona S.r.l. · Verona, Italy
  • Pan American Oncology Trials, LLC · San Juan, Puerto Rico
  • Auxilio Mutuo Cancer Center · San Juan, Puerto Rico
  • Hospital General Universitario Dr. Balmis · Alicante, Spain
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • ICO Girona · Girona, Spain
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitario Virgen de la Victoria · Málaga, Spain
  • Hospital Universitario Virgen del Rocio · Seville, Spain
  • Hospital Universitario Virgen Macarena · Seville, Spain
  • Hospital Universitari i Politecnic La Fe · Valencia, Spain
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    23 sites added, 23 sites removed
    Show 23 added (9 Spain, 4 Germany, 4 Italy, 2 France, 2 Ireland, 2 Puerto Rico)
    • Hopital Saint Joseph - Paris · Paris, France
    • Institut Gustave Roussy · Villejuif, France
    • Evangelische Lungenklinik Berlin · Berlin, Germany
    • Vivantes Klinikum im Friedrichshain · Berlin, Germany
    • Vivantes Klinikum Neukoelln · Berlin, Germany
    • Vivantes Klinikum Spandau · Berlin, Germany
    • Beaumont Hospital · Dublin, Ireland
    • St James's Hospital · Dublin, Ireland
    • Istituto Nazionale per la Ricerca sul Cancro di Genova · Genova, Italy
    • Ospedale Santa Maria delle Croci · Ravenna, Italy
    • Regina Elena National Cancer Institute · Roma, Italy
    • CRC - Centro Ricerche Cliniche di Verona S.r.l. · Verona, Italy
    • Pan American Oncology Trials, LLC · San Juan, Puerto Rico
    • Auxilio Mutuo Cancer Center · San Juan, Puerto Rico
    • Hospital General Universitario Dr. Balmis · Alicante, Spain
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • ICO Girona · Girona, Spain
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario Virgen de la Victoria · Málaga, Spain
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    • Hospital Universitario Virgen Macarena · Seville, Spain
    • Hospital Universitari i Politecnic La Fe · Valencia, Spain
    Show 23 removed
    • Institut Gustave Roussy · Villejuif, France
    • Hopital Saint Joseph - Paris · Paris, France
    • Evangelische Lungenklinik Berlin · Berlin, Germany
    • Vivantes Klinikum im Friedrichshain · Berlin, Germany
    • Vivantes Klinikum Neukoelln · Berlin, Germany
    • Vivantes Klinikum Spandau · Berlin, Germany
    • Beaumont Hospital · Dublin, Ireland
    • St James's Hospital · Dublin, Ireland
    • Istituto Nazionale per la Ricerca sul Cancro di Genova · Genova, Italy
    • Ospedale Santa Maria delle Croci · Ravenna, Italy
    • Regina Elena National Cancer Institute · Roma, Italy
    • CRC - Centro Ricerche Cliniche di Verona S.r.l. · Verona, Italy
    • Pan American Oncology Trials, LLC · San Juan, Puerto Rico
    • Auxilio Mutuo Cancer Center · San Juan, Puerto Rico
    • Hospital General Universitario Dr. Balmis · Alicante, Spain
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • ICO Girona · Girona, Spain
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario Virgen de la Victoria · Málaga, Spain
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    • Hospital Universitario Virgen Macarena · Seville, Spain
    • Hospital Universitari i Politecnic La Fe · Valencia, Spain

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06635824
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Oct 10, 2024
Start date
Nov 25, 2024
Primary completion
Jul 30, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acasunlimab

Start the discussion